Logo 1 Logo 2

Clinical Trial Details

Trial ID: L3954
Source ID: NCT00791895
Associated Drug: Biphasic Insulin Aspart 30
Title: Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes|Diabetes Mellitus, Type 2
Interventions: DRUG: biphasic insulin aspart 30
Outcome Measures: Primary: Percentage of subjects achieving HbA1c below 6.5%, after 16, 32 and 48 weeks, respectively |
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 102
Study Type: INTERVENTIONAL
Study Designs: Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2003-06-26
Completion Date: 2004-11-29
Results First Posted:
Last Update Posted: 2017-02-24
Locations: Novo Nordisk Investigational Site, Phoenix, Arizona, 85006, United States|Novo Nordisk Investigational Site, La Jolla, California, 92093-0694, United States|Novo Nordisk Investigational Site, La Jolla, California, 92093-0831, United States|Novo Nordisk Investigational Site, Deland, Florida, 32720, United States|Novo Nordisk Investigational Site, Wichita, Kansas, 67205, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, 68114, United States|Novo Nordisk Investigational Site, Albany, New York, 12206, United States|Novo Nordisk Investigational Site, Cleveland, Ohio, 44115, United States|Novo Nordisk Investigational Site, Medford, Oregon, 97504, United States|Novo Nordisk Investigational Site, Memphis, Tennessee, 38119, United States|Novo Nordisk Investigational Site, Dallas, Texas, 75231, United States|Novo Nordisk Investigational Site, Houston, Texas, 77030, United States|Novo Nordisk Investigational Site, Ogden, Utah, 84403, United States|Novo Nordisk Investigational Site, Renton, Washington, 98057, United States|Novo Nordisk Investigational Site, Milwaukee, Wisconsin, 53209, United States
URL: https://clinicaltrials.gov/show/NCT00791895

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress